The healthcare sub-sector map

Why "healthcare" isn't one sector

Ask an interviewer to name the single hardest thing about covering healthcare, and most will say some version of the same thing: the sector isn't one business, it's several unrelated businesses that happen to share a customer, the patient, at some point in their respective value chains. A biopharma company and a hospital system both exist because people get sick, but that's roughly where the resemblance ends. One has no revenue and years of losses before a single dollar comes in the door. The other has been generating steady, if thin, margins from day one. Interviewers use sub-sector questions constantly, because a candidate who treats "healthcare" as a single valuation grammar reveals immediately that they haven't done real homework on the group.

This article is the map: the six sub-sectors a healthcare coverage banker needs to be able to name unprompted, what each one actually sells, how each one makes money, and how each one gets valued. The overview lives here; the deep mechanics for the sub-sectors that carry the most interview weight, biopharma and services and payors, live in their own articles linked throughout.

The map

Two things jump out from that table, and interviewers expect you to be able to say both out loud. First, only two rows have a customer who pays directly and immediately for what they receive in the way a normal consumer business does: life science tools, where the customer is a lab or a biopharma company buying with its own budget, and part of medtech, where a hospital purchases equipment. Everywhere else, a third-party payor sits between the seller and the person actually receiving care, which is the reimbursement dynamic covered fully in healthcare services: providers and payors. Second, only one row, biopharma, can be valued at a large size with zero current revenue, because the entire value proposition sits in a pipeline of future, uncertain products rather than a business that is already operating.

Biopharma: the outlier

Biopharma companies discover, develop, and eventually sell prescription drugs, and the business divides cleanly into two very different postures. A clinical-stage company has no approved products and no meaningful revenue, and its entire value sits in a pipeline of drug candidates working through preclinical research and clinical trials. A commercial-stage company has at least one approved, marketed product generating real revenue, though it usually still carries a pipeline of earlier-stage assets alongside its commercial business.

That split matters enormously for valuation. A commercial-stage biopharma company can be valued with the same core toolkit used everywhere else in banking: DCF, trading comps, precedent transactions. A clinical-stage company cannot, because there's no revenue or earnings to build a multiple from and no reliable near-term cash flow for a plain DCF to discount. The sector's answer, risk-adjusted net present value, explicitly prices the probability that a drug candidate never reaches the market at all, and it's covered start to finish in how biotech companies are valued. The business model underneath both postures, including why a pipeline is the real long-term asset even for a commercial-stage company and why patents expiring is a genuine threat to future revenue, is in pharma business models, pipelines, and patent cliffs.

Within biopharma itself, it's worth distinguishing large, diversified pharma companies from smaller, single-asset or few-asset biotechs, because the two face different versions of the same risk. A large pharma company spreads its risk across dozens of pipeline programs and a portfolio of already-marketed products, so any one trial failure barely moves the total valuation. A small biotech often has its entire value riding on one or two clinical programs, which is why a single trial result can move its stock by a large multiple of its size in a single day. Generics and specialty pharma companies sit slightly apart again: a generics manufacturer competes on manufacturing scale and cost once a branded drug's exclusivity has expired, rather than on pipeline innovation, so it gets valued closer to an industrials business than to an innovator biopharma company.

Medtech and life science tools: industrials in scrubs

Medtech companies sell devices and equipment used to diagnose or treat patients, ranging from a simple disposable product to a complex piece of capital equipment implanted or used in surgery. A large share of the sector runs on a razor-and-blade model: sell the durable equipment once, then sell the disposable consumables that equipment requires for every single use, for years. That recurring consumables stream is what makes medtech valuation look far more like an industrials or consumer-durables business than a biopharma one, since once a device has real market adoption, its cash flow is genuinely predictable in a way a clinical-stage drug candidate's never is.

Life science tools and diagnostics companies sell instruments, reagents, and lab tests, but their customers are different from a hospital's typical medtech supplier relationship. A tools company sells to biopharma companies and academic and clinical labs conducting research and development, which makes it a picks-and-shovels play on the broader biopharma industry: it can grow even when a specific drug program fails, because its customers keep running experiments regardless of any one program's outcome. A diagnostics company sells tests used to detect or monitor disease, and its growth depends on physician adoption and, again, reimbursement, since a test that isn't covered by payors struggles to get ordered at scale regardless of its clinical value. Both sub-sectors are covered together, with the specific unit economics that distinguish them from a pure biopharma name, in medtech and life science tools economics.

Providers, payors, and the reimbursement engine

Providers deliver patient care directly: hospitals, health systems, physician groups, surgery centers, home health and hospice agencies, and other businesses where a clinician is the one generating revenue by treating a patient. Payors are the other side of that relationship: health insurers and managed care organizations that collect premiums and pay claims on behalf of the patients and employers they cover.

Neither side sets prices the way a normal business does. A provider's revenue is a function of two separate levers, how many patients it treats and what rate it's paid per treatment by whichever payor is footing the bill, government or commercial. A payor's profitability is a function of how well the premiums it collects cover the claims it pays out, a relationship with its own specific vocabulary. Interviewers push hard on this framework because it's the single clearest way to test whether a candidate actually understands healthcare economics versus having memorized a generic banking script, and the full mechanics are in healthcare services: providers and payors.

Healthcare IT: software with a healthcare customer

Healthcare IT sits apart from the other five sub-sectors because its underlying business model, subscription software, isn't unique to healthcare at all. A company selling electronic health record software, scheduling tools, or billing and claims software to providers and payors gets valued the way any software business gets valued elsewhere: on recurring revenue growth, gross margin, and customer retention. What makes it a healthcare sub-sector rather than a generic software one is that its growth is gated by its customers' budgets and regulatory environment, not independent of them. A hospital system tightening its own margins because of a reimbursement rate dispute with a major payor will slow its software spending too, which means an HCIT analyst still needs to understand the provider and payor dynamics driving their own customers' budgets even though the HCIT company itself never touches reimbursement directly.

How coverage teams actually draw the lines

Banks don't always split their org charts exactly along these six categories. Some banks run biopharma as its own dedicated team given how differently it needs to be valued, and group medtech, tools, providers, payors, and HCIT together as a broader "healthcare services and products" team. Others split more finely, with separate desks for services and for payors given how different a hospital roll-up model looks from an insurance company model. What stays constant across every bank is the underlying fault line: biopharma's valuation logic is different enough from everything else in the sector that it almost always gets treated as its own lane, and the reimbursement-driven businesses, providers, payors, and to a lesser extent medtech, tend to cluster together because they share the volume-and-rate framework even when their specific business models differ.

Knowing this map cold, and being able to place a company into the right box within a few seconds of hearing its name, is table stakes for a healthcare interview. It's also the fastest way to signal genuine interest in the group rather than a generic "I like healthcare" answer, a distinction covered fully in how to answer why healthcare.

Practice question

Walk me through the major sub-sectors within healthcare and how their business models differ.

I'd split healthcare into six pieces. Biopharma discovers and sells prescription drugs, and it's the outlier of the group because a pre-revenue, clinical-stage company can be worth billions on pipeline value alone, valued with a risk-adjusted approach rather than standard multiples. Medtech sells devices, often on a model where the durable equipment is sold once and disposable consumables get sold repeatedly after that, which gives it real, predictable recurring cash flow once a product has market traction. Life science tools and diagnostics sell instruments, reagents, and tests, mostly to biopharma and lab customers rather than to patients directly, so they act as a picks-and-shovels play on the broader industry's research spending. Providers, meaning hospitals, physician groups, and home health, deliver patient care directly and get paid by insurers or government programs rather than by the patient, so their revenue comes down to patient volume times reimbursement rate. Payors, the health insurers, collect premiums and pay out claims, so their economics are about how well premium revenue covers claims. Healthcare IT sells software to all of the above, and it's valued like any subscription software business, but its growth is still gated by its customers' reimbursement and regulatory environment. The throughline is that only biopharma has real binary, science-driven risk. Everything else is a variation on a reimbursement-and-volume story.

What the interviewer is listening for: whether you can name all six categories cleanly and pair each one with the right valuation logic, since that pairing is the actual skill being tested. A candidate who lumps biopharma in with the rest, or who can't explain why reimbursement matters to providers and medtech alike, hasn't internalized the map yet.